Fresenius SE & Co (FSNUY) AI Stock Analysis

Fresenius SE & Co

(Other OTC:FSNUY)

Select Model

Rating:77Outperform

Price Target:$13.50▲(1.21% Upside)

Action:reiterated

Date:08/10/26

Driven by recovering financial health and positive earnings guidance signaling growth potential; technical indicators support upside, with fair valuation adding stability.

Positive Factors

Diversified healthcare platformFresenius combines pharmaceuticals, biopharma, medical technologies, nutrition and care delivery, creating multiple growth engines. This breadth supports customer reach, reduces reliance on one healthcare niche, and provides several avenues for durable expansion over the next several quarters.

Negative Factors

FDA remediation riskThe FDA OAI creates an ongoing compliance and remediation burden at a U.S. manufacturing site. Management expects no material full-year impact, but unresolved findings could still disrupt execution, increase costs, or constrain future production flexibility if corrective actions take longer than planned.

Fresenius SE & Co (FSNUY) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $120.31B
Dividend Yield: 2.25%
Average Volume (3M): 100.91K
Price to Earnings (P/E): 17.4
Beta (1Y): 0.36
Revenue Growth: 12.91%
EPS Growth: 44.43%
Country: US
Employees: 178,394
Sector: General
Sector Strength: 55
Industry: Medical - Care Facilities

Fresenius SE & Co Business Overview & Revenue Model

Company Description

Fresenius SE & Co. KGaA is a healthcare group, which engages in the provision of products and services for dialysis, hospitals, and outpatient medical care. It operates through the following segments: Fresenius Medical Care, Fresenius Kabi, Fresenius...

Fresenius SE & Co Earnings Call Summary

Earnings Call Date:Aug 03, 2026(Q2-2026)|% Change Since:3.50%|Next Earnings Date:Nov 03, 2026

Earnings Call SentimentPositive

The call was decisively positive: management reported broad‑based operational momentum across Kabi, biopharma, MedTech and Helios, delivered strong Q2 results (core EPS +14% CER, EBIT +10% CER), expanded margins and ROIC, strengthened cash generation and raised full‑year core EPS guidance to 10%–15%. Noted risks — an OAI at a U.S. manufacturing site, isolated manufacturing adjustments, China VBP headwinds, regional softness in parts of Helios and external input‑cost pressures — are acknowledged and being managed, but they do not materially detract from the upbeat operational and financial story presented.

Positive Updates

Raised Full‑Year Core EPS Guidance

Upgraded full‑year core EPS growth guidance to 10%–15% at constant currency (previously 5%–10%), reflecting strong H1 delivery and confidence in second‑half phasing.

Negative Updates

FDA Inspection — OAI at Melrose Park

U.S. FDA inspection resulted in 'Official Action Indicated' (OAI) status at the Melrose Park site (other U.S. sites VAI). Management expects no material impact on production, supply or full‑year financials but remediation is required and remains a risk to monitor.

Company Guidance

Fresenius raised its full‑year core EPS growth guidance to 10–15% at constant currency (up from 5–10%), driven by strong H1 results (Q2 core EPS +14% CER, EBIT +10% CER, group EBIT margin +60 bps to 12.3%); key planning assumptions include Kabi EBIT margin at the upper end of the 16.5–17% range, interest expense slightly below prior year, CapEx around 5.5% of revenue, and a modest FX sensitivity (spot rates as of 30 June would give <1% upside to reported revenue, EBIT and net income). Management flagged Kabi’s growth vectors (Kabi organic +7% in Q2, biopharma +38%, growth vectors +12%, MedTech +11%) and the full annualisation of China keto/VBP effects from Q3 as important drivers, noted Helios seasonality (Q3) and a tough Q4 compare (surcharge to Oct‑26), reiterated Helios’ structural EBIT margin ambition of 10–12% and expected EBIT growth for 2027, and emphasized balance‑sheet strength (net debt/EBITDA ~2.6x within 2.5–3x target, LTM operating cash flow €2.8bn, LTM free cash flow €1.6bn, LTM cash conversion 1.2, ROIC ~6.9% vs 6–8% ambition).

Fresenius SE & Co Financial Statement Overview

Summary

Strong recovery in revenue and profitability, with improved margins and reduced debt, offset by cash flow volatility from past restructuring.

Income Statement

75Positive

Balance Sheet

80Positive

Cash Flow

65Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	23.53B	21.97B	21.83B	22.30B	40.84B	37.52B
Gross Profit	5.94B	5.47B	5.38B	5.06B	10.72B	10.31B
EBITDA	3.42B	3.17B	3.14B	2.73B	3.10B	6.86B
Net Income	1.53B	1.21B	471.00M	-594.00M	1.37B	1.82B
Balance Sheet
Total Assets	41.83B	41.38B	43.55B	45.28B	76.42B	71.96B
Cash, Cash Equivalents and Short-Term Investments	1.28B	1.58B	2.05B	2.56B	2.35B	2.75B
Total Debt	11.41B	11.93B	13.58B	15.83B	27.76B	27.16B
Total Liabilities	21.44B	21.62B	23.26B	25.63B	44.20B	42.67B
Stockholders Equity	19.69B	19.10B	19.54B	19.00B	20.41B	19.00B
Cash Flow
Free Cash Flow	1.42B	1.15B	1.52B	3.32B	2.28B	3.03B
Operating Cash Flow	2.93B	2.59B	2.45B	4.46B	4.20B	5.08B
Investing Cash Flow	-759.28M	-904.82M	-510.00M	-3.19B	-2.61B	-2.82B
Financing Cash Flow	-2.21B	-2.32B	-2.18B	-1.38B	-1.60B	-1.45B

Fresenius SE & Co Technical Analysis

Technical Analysis SentimentPositive

Last Price13.34

Price Trends

50DMA12.84Positive

100DMA12.57Positive

200DMA12.79Positive

Market Momentum

MACD0.11Negative

RSI65.12Neutral

STOCH93.26Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FSNUY, the sentiment is Positive. The current price of 13.34 is above the 20-day moving average (MA) of 12.51, above the 50-day MA of 12.84, and above the 200-day MA of 12.79, indicating a bullish trend. The MACD of 0.11 indicates Negative momentum. The RSI at 65.12 is Neutral, neither overbought nor oversold. The STOCH value of 93.26 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FSNUY.

Fresenius SE & Co Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

FSNUY against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
THC	84Outperform	$21.75B	7.87	60.60%	―	6.23%	136.09%
FSNUY	77Outperform	$29.86B	17.38	7.89%	2.25%	12.91%	44.43%
OPCH	69Neutral	$4.77B	23.93	15.83%	―	5.95%	5.33%
DVA	62Neutral	$11.79B	14.39	-133.21%	―	6.38%	36.05%
HCA	61Neutral	$98.85B	57.42	-100.45%	0.65%	5.82%	16.59%
FMS	60Neutral	$12.03B	12.17	7.21%	3.85%	6.76%	57.96%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%

* General Sector Average

Performance Comparison

FSNUY and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
FSNUY	Fresenius Se	13.34	-0.86	-6.04%
OPCH	Option Care Health Inc	31.83	5.41	20.48%
DVA	DaVita Inc.	187.50	68.45	57.50%
FMS	Fresenius Medical Care	22.47	-3.16	-12.34%
HCA	Hca Healthcare	473.19	14.77	3.22%
THC	Tenet Healthcare Corp.	273.25	71.86	35.68%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 10, 2026

Fresenius SE & Co AI Stock Analysis